AI Insight
Researchers at Cambridge have identified a key protein that may serve as a predictor for preeclampsia and fetal growth restriction, which are leading causes of stillbirth and maternal-newborn illness. The discovery provides insight into why placental cells fail to properly invade the uterine wall in these conditions. This finding could enable development of diagnostic tests to identify high-risk pregnancies and lead to new therapeutic interventions.
Why it matters
Early identification of women at risk for preeclampsia and fetal growth restriction could allow for closer monitoring and timely interventions, potentially reducing stillbirths and complications for mothers and babies. The protein target may also offer a pathway for developing new treatments for these currently difficult-to-manage pregnancy conditions.
Understand the Science
Cambridge scientists have identified a key protein that could act as a predictor for preeclampsia and fetal growth restriction, two of the major causes of stillbirth and illness among mothers and newborns. The discovery helps explain why placental cells fail to properly “invade” the uterus in these related conditions and could lead to tests that help identify those at greatest risk and new treatments. The findings are published in Nature Medicine.
Source: Preeclampsia discovery could lead to new test and treatments for at-risk pregnancies